Eli Lilly and Company
Treatment of primary biliary cholangitis and primary sclerosing cholangitis with baricitinib

Last updated:

Abstract:

Methods of treating Primary Biliary Cholangitis and/or Primary Sclerosing Cholangitis with baricitinib, including formulations and dose regimens. The amount of baricitinib may be administered as a 4 mg tablet or pill that includes one or more excipients. The amount of baricitinib may be administered daily or at some other frequency.

Status:
Grant
Type:

Utility

Filling date:

10 Oct 2019

Issue date:

14 Dec 2021